Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial

Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial

Introduction Progressive supranuclear palsy (PSP) is a neurodegenerative disorder for which there are currently no disease-modifying therapies. The neuropathology of PSP is associated with the accumulation of hyperphosphorylated tau in the brain. We have previously shown that protein phosphatase 2 a...

Full description

Saved in:
Bibliographic Details
Main Authors: Kelly L Bertram, Lucy Vivash, Dennis Velakoulis, Leonid Churilov, Thomas Kimber, David Darby, Terence J O’Brien, Charles B Malpas, Christopher M Hovens, Simon J G Lewis, Joanne Fielding, Andrew H Evans, Stephen Tisch, John D O’Sullivan, Ian H Harding, Meaghan Clough, Cassandra Marotta, Scott Kolbe, Meng Law
Format: Article
Language:English
Published: BMJ Publishing Group 2021-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/12/e055019.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/11/12/e055019.full

Similar Items